Evidence map›Paper›PMID 42044158›Full record

ArticleJCI insight2026

Single-cell multiomic analysis of mesenchymal cells reveals molecular signatures and regulators of lung allograft fibrosis.

Lu Lu, A Patrick McLinden, Natalie M Walker, Ragini Vittal, Yichen Wang, Fatemeh Fattahi, Stephen T Russell, Michael P Combs, Joshua D Welch, Vibha N Lama

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Lu LuDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.
A Patrick McLindenDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
Natalie M WalkerDivision of Pulmonary & Critical Care, School of Medicine, and.
Ragini VittalDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
Yichen WangDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.
Fatemeh FattahiDivision of Pulmonary & Critical Care, School of Medicine, and.
Stephen T RussellDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
Michael P CombsDivision of Pulmonary & Critical Care, School of Medicine, and.
Joshua D WelchDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA.
Vibha N LamaDivision of Pulmonary, Allergy, Critical Care, and Sleep Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.

Funding

Translational Dysregulation Driving Mesenchymal Cell Fibrogenic Transformation and Chronic Lung Allograft DysfunctionR01HL094622 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAMA, VIBHA N · 2009 to 2023
$5.9M
Pathogenesis of Restrictive Allograft Syndrome Post-Lung TransplantationR01HL162171 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAMA, VIBHA N · 2022 to 2025
$2.7M
NHLBI NIH HHS R01 HL094622NHLBI NIH HHS R01 HL162171
6 · The paper itself

Abstract

Survival after lung transplantation is limited by chronic, progressive graft failure, termed chronic lung allograft dysfunction (CLAD). Graft-resident mesenchymal cells (MCs) drive CLAD pathogenesis and exhibit stable dysregulated signaling, yet the transcriptomic and epigenomic drivers underlying this fibrogenic transformation remain elusive. We used single-cell multiomic profiling to characterize gene expression and chromatin accessibility in MCs isolated from bronchoalveolar lavage fluid of lung transplant recipients with and without CLAD, collected early after transplantation or after disease onset. MCs obtained after CLAD onset demonstrated a distinct transcriptomic signature compared with non-CLAD controls, enabling classification of disease status at the single-cell level with greater than 98% accuracy using signature genes. Chromatin accessibility analyses identified enrichment of CCAAT-enhancer-binding protein family transcription factors, specifically CEBPD, in CLAD MCs. MCs early after transplantation showed minimal accessibility differences, suggesting that CEBPD-associated regulatory changes emerge over time. Integration analyses identified 8 MC states and a CLAD-specific shift toward a fibrotic state. CEBPD, SOX4, and FOXP2 were identified as putative regulators of this state with substantial overlap in predicted targets. Targeting CEBPD reversed fibrotic phenotypes of CLAD MCs (decreased ECM expression, contractility, proliferation, and migration). Together, these data provide insights into transcriptomic and epigenomic changes in posttransplant MCs, facilitating the nomination of biomarkers and therapeutic targets.

Indexed as

Lung TransplantationMesenchymal Stem CellsPulmonary FibrosisAllograftsBronchoalveolar Lavage FluidFemaleGene Expression ProfilingGraft RejectionHumansLungMaleMultiomicsSingle-Cell AnalysisSingle-Cell Gene Expression AnalysisTranscriptomeFibrosisGeneticsOrgan transplantationPulmonology

Identifiers

PMID42044158
PMCPMC13460852

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.